Memphasys Limited (MEM.AX)
AUD 0.01
(-16.67%)
AUD 0.01
(-16.67%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 4.13 Million AUD | -20.38% |
| 2023 | 5.69 Million AUD | 8.41% |
| 2022 | 5.25 Million AUD | 58.52% |
| 2021 | 3.31 Million AUD | 441.56% |
| 2020 | -969.65 Thousand AUD | -11.86% |
| 2019 | -866.83 Thousand AUD | -409.33% |
| 2018 | 280.22 Thousand AUD | -95.84% |
| 2017 | 6.73 Million AUD | 38.41% |
| 2016 | 4.86 Million AUD | -6.33% |
| 2015 | 5.19 Million AUD | -21.65% |
| 2014 | 6.63 Million AUD | 255.3% |
| 2013 | 1.86 Million AUD | 108.57% |
| 2012 | 894.97 Thousand AUD | 156.97% |
| 2011 | 348.27 Thousand AUD | 131.64% |
| 2010 | -1.1 Million AUD | -398.76% |
| 2009 | 368.39 Thousand AUD | -44.32% |
| 2008 | 661.61 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 4.48 Million AUD | -21.26% |
| 2024 Q2 | 5.52 Million AUD | 0.0% |
| 2024 Q4 | 4.13 Million AUD | 0.0% |
| 2023 Q2 | 3.36 Million AUD | 0.0% |
| 2023 Q4 | 5.69 Million AUD | 0.0% |
| 2023 FY | 5.69 Million AUD | 8.41% |
| 2022 Q2 | 3.64 Million AUD | 0.0% |
| 2022 Q4 | 5.25 Million AUD | 0.0% |
| 2022 FY | 5.25 Million AUD | 58.52% |
| 2021 FY | 3.31 Million AUD | 441.56% |
| 2021 Q4 | 3.31 Million AUD | 0.0% |
| 2021 Q2 | -102.31 Thousand AUD | 0.0% |
| 2020 Q2 | -2.73 Million AUD | 0.0% |
| 2020 FY | -969.65 Thousand AUD | -11.86% |
| 2020 Q4 | -969.65 Thousand AUD | 0.0% |
| 2019 FY | -866.83 Thousand AUD | -409.33% |
| 2019 Q4 | -866.83 Thousand AUD | 0.0% |
| 2019 Q2 | 910.92 Thousand AUD | 0.0% |
| 2018 FY | 280.22 Thousand AUD | -95.84% |
| 2018 Q4 | 280.22 Thousand AUD | 0.0% |
| 2018 Q2 | -695.85 Thousand AUD | 0.0% |
| 2017 Q4 | 6.76 Million AUD | 0.0% |
| 2017 FY | 6.73 Million AUD | 38.41% |
| 2017 Q2 | 5.73 Million AUD | 0.0% |
| 2016 Q2 | 5.85 Million AUD | 0.0% |
| 2016 FY | 4.86 Million AUD | -6.33% |
| 2016 Q4 | 4.86 Million AUD | 0.0% |
| 2015 Q4 | 5.19 Million AUD | 0.0% |
| 2015 Q2 | 3.65 Million AUD | 0.0% |
| 2015 FY | 5.19 Million AUD | -21.65% |
| 2014 Q2 | 2.14 Million AUD | 2931.67% |
| 2014 FY | 6.63 Million AUD | 255.3% |
| 2014 Q4 | 6.63 Million AUD | 14376.91% |
| 2014 Q3 | -46.45 Thousand AUD | -102.16% |
| 2014 Q1 | -75.83 Thousand AUD | -104.06% |
| 2013 Q2 | -697.69 Thousand AUD | 0.0% |
| 2013 Q1 | -697.69 Thousand AUD | -177.96% |
| 2013 Q4 | 1.86 Million AUD | 1131.61% |
| 2013 FY | 1.86 Million AUD | 108.57% |
| 2013 Q3 | -180.94 Thousand AUD | 74.07% |
| 2012 FY | 894.97 Thousand AUD | 156.97% |
| 2012 Q4 | 894.97 Thousand AUD | 0.0% |
| 2011 Q4 | 348.27 Thousand AUD | 0.0% |
| 2011 FY | 348.27 Thousand AUD | 131.64% |
| 2010 FY | -1.1 Million AUD | -398.76% |
| 2010 Q4 | -1.1 Million AUD | 0.0% |
| 2009 Q4 | 368.39 Thousand AUD | 0.0% |
| 2009 FY | 368.39 Thousand AUD | -44.32% |
| 2008 Q4 | -695.56 Thousand AUD | 0.0% |
| 2008 FY | 661.61 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | 589.293% |
| Acrux Limited | -1.45 Million AUD | 383.633% |
| Actinogen Medical Limited | -9.13 Million AUD | 145.286% |
| AnteoTech Limited | -5 Million AUD | 182.682% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 125.988% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 132.525% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | 521.071% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 133.136% |
| Amplia Therapeutics Limited | -1.82 Million AUD | 326.771% |
| Avecho Biotechnology Limited | -5.32 Million AUD | 177.598% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | 682.81% |
| Biome Australia Limited | -1.56 Million AUD | 364.612% |
| Biotron Limited | -386.06 Thousand AUD | 1171.151% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 105.214% |
| BTC Health Limited | -2.02 Million AUD | 304.503% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | 235.453% |
| CSL Limited | 15.76 Billion AUD | 99.974% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 103.029% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 102.26% |
| Cynata Therapeutics Limited | -6.2 Million AUD | 166.641% |
| Dimerix Limited | -21.99 Million AUD | 118.804% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 121.882% |
| Hexima Limited | -2.22 Million AUD | 285.758% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | 433.926% |
| Immuron Limited | -11.48 Million AUD | 136.01% |
| Immutep Limited | -122.18 Million AUD | 103.384% |
| Imugene Limited | -91.56 Million AUD | 104.517% |
| Invex Therapeutics Ltd | -6.02 Million AUD | 168.636% |
| Nanollose Limited | -96.22 Thousand AUD | 4397.607% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 124.192% |
| Noxopharm Limited | -2.31 Million AUD | 278.254% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | 183.473% |
| Nyrada Inc. | -4.76 Million AUD | 186.707% |
| Orthocell Limited | -19.92 Million AUD | 120.755% |
| PharmAust Limited | -9.71 Million AUD | 142.571% |
| Patrys Limited | -2.24 Million AUD | 284.56% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 123.521% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | 165.393% |
| Prescient Therapeutics Limited | -10.16 Million AUD | 140.692% |
| PYC Therapeutics Limited | -65.76 Million AUD | 106.288% |
| Race Oncology Limited | -17.18 Million AUD | 124.058% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 122.263% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | 221.767% |
| Starpharma Holdings Limited | -19.83 Million AUD | 120.852% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 103.909% |
| Tissue Repair Ltd | -16.44 Million AUD | 125.153% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 18.392% |